Placeholder Banner

BIO Comments on Prescription Drug-Use-Related Software

April 29, 2019

BIO submitted comments on the Food and Drug Administration’s (FDA) open docket on Prescription Drug-Use-Related Software.

In the comments, BIO says it’s important to encourage innovation and ensure developers are aware of regulatory pathways available for bringing novel technologies to the health care and medical markets. There’s currently insufficient clarity about the regulatory pathway and jurisdiction of drug-use-related software technology.

However, BIO also expresses concern about FDA’s intent to regulate beyond the accepted confines of “labeling,” which has been recognized by the industry and reinforced by the courts. Elements of the framework could stifle innovation. BIO urges FDA to more specifically outline the types of communications it intends to regulate, how review will be coordinated across FDA Centers, and how the framework will interact with other guidance, among other issues.

Download Full Comments Below
BIO Comments Prescription Drug Use Related Software FDA–2018-N-3017
Read full comment letter below
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…